Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Ribaxamase

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Theriva™ Gets Positive DSMC Review For SYN-004 In HCT Trial
    Theriva™ Gets Positive DSMC Review For SYN-004 In HCT Trial

    03 Oct 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/10/03/2957647/0/en/Theriva-Biologics-Announces-Positive-Outcome-of-Data-and-Safety-Monitoring-Committee-DSMC-Review-in-Phase-1b-2a-Clinical-Trial-of-SYN-004-ribaxamase-in-Allogeneic-Hematopoietic-Cel.html

    GLOBENEWSWIRE
    03 Oct 2024
    Share Share
    Theriva Announces Presentation of Safety Data from Ph1b/2a Trial of SYN-004
    Theriva Announces Presentation of Safety Data from Ph1b/2a Trial of SYN-004

    16 Feb 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/02/16/2610106/0/en/Theriva-Biologics-Announces-Presentation-of-Safety-and-Pharmacokinetic-Data-from-Cohort-1-of-the-Phase-1b-2a-Clinical-Trial-of-SYN-004-ribaxamase-in-Allogeneic-Hematopoietic-Cell-T.html

    GLOBENEWSWIRE
    16 Feb 2023
    Share Share
    Synthetic Biologics Announces +ve Outcome of (DSMC) Review in Ph1b/2a SYN-004
    Synthetic Biologics Announces +ve Outcome of (DSMC) Review in Ph1b/2a SYN-004

    27 Sep 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/09/27/2523271/0/en/Synthetic-Biologics-Announces-Positive-Outcome-of-Data-and-Safety-Monitoring-Committee-DSMC-Review-in-Phase-1b-2a-Clinical-Trial-of-SYN-004-ribaxamase-in-Allogeneic-Hematopoietic-C.html

    GLOBENEWSWIRE
    27 Sep 2022
    Share Share
    Synthetic Biologics Announces Washington University School of Medicine
    Synthetic Biologics Announces Washington University School of Medicine

    22 Dec 2020

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/synthetic-biologics-announces-washington-university-school-of-medicine-in-st-louis-irb-approval-of-the-syn-004-ribaxamase-phase-1b2a-clinical-protocol-301197187.html

    PRNEWSWIRE
    22 Dec 2020
    Share Share
    Synthetic Biologics Announces Washington USM in St. Louis IRB
    Synthetic Biologics Announces Washington USM in St. Louis IRB

    22 Dec 2020

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/synthetic-biologics-announces-washington-university-school-of-medicine-in-st-louis-irb-approval-of-the-syn-004-ribaxamase-phase-1b2a-clinical-protocol-301197187.html

    PRNEWSWIRE
    22 Dec 2020
    Share Share